SCHAUMBURG, Ill. - Oct. 31, 2008 – Fresenius SE parent company of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) will announce third quarter earnings on November 4, 2008 at 2:00 p.m. CET/8:00 a.m. EST/ 7:00 a.m. CST. Fresenius Kabi is a business segment of Fresenius SE.
Fresenius Kabi acquired the Schaumburg, Illinois-based APP Pharmaceuticals on September 10, 2008. Under the terms of the agreement, Fresenius acquired the outstanding common stock of APP for $23.00 in cash per share (the "Cash Purchase Price") plus a Contingent Value Right (CVR) that could deliver up to an additional $980 million, or $6.00 per CVR in cash, pending achievement of certain financial targets (payable in Q2 2011).
Holders of CVR’s and other interested parties may listen to the Fresenius earnings call at www.fresenius.com. A replay of the webcast will be available on the Fresenius Web site following the live presentation.
About Fresenius SE
Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2007, group sales were approximately EUR 11.4 billion. On June 30, 2008 the Fresenius Group had 117,453 employees worldwide. For more information visit the company's website at www.fresenius.com.
About Fresenius Kabi
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi's core product range includes infusion solutions for fluid substitution, blood volume expansion and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With its philosophy "Caring for life" and a comprehensive product portfolio, the company aims at improving the quality of life of patients all over the world. On June 30, 2008 the company had 18,323 employees. In 2007, Fresenius Kabi achieved sales of EUR 2,030 million and an operating profit of EUR 332 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE.
About APP Pharmaceuticals, Inc.
APP is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations.
Investor and Media Inquiries:
Hill & Knowlton
Birgit Grund, Senior Vice President
++49 6172 608 2485